{
    "clinical_study": {
        "@rank": "137673", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single arm, multicenter long-term extension study of WA19926 will evaluate\n      the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to\n      severe rheumatoid arthritis who have completed the 104-week WA19926 core study. Eligible\n      patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104\n      weeks."
        }, 
        "brief_title": "A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients who complete their last WA19926 core study visit (Week 104) and who may\n             benefit from study drug treatment, at baseline or later if they are in remission\n             DAS28 at Week 104 of WA19926, according to the Investigator's assessment\n\n          -  No current or recent adverse event or laboratory finding preventing the use of the\n             study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit\n\n          -  Women of childbearing potential must agree to use adequate contraception as defined\n             by protocol during and up to 3 months after treatment\n\n        Exclusion Criteria:\n\n          -  Pregnant females\n\n          -  Patients who have withdrawn prematurely from the WA19926 core study for any reason\n\n          -  Treatment with any investigational agent or cell-depleting therapies since the last\n             administration of study drug in WA19926\n\n          -  Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent,\n             or a T-cell costimulation modulator since the last administration of study drug in\n             WA19926\n\n          -  Immunization with a live/attenuated vaccine since the last administration of study\n             drug in WA19926\n\n          -  Diagnosis since last WA19926 visit (Week 104) of rheumatic autoimmune disease other\n             than rheumatoid arthritis\n\n          -  Diagnosis since last WA19926 visit (Week 104) of inflammatory joint disease other\n             than rheumatoid arthritis\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine\n             monoclonal antibodies, including tocilizumab and its excipients\n\n          -  Evidence of severe uncontrolled concomitant disease or disorder\n\n          -  Known active or history of recurrent infections\n\n          -  Active tuberculosis requiring treatment in the previous 3 years\n\n          -  History of alcohol, drug or chemical abuse since inclusion in the WA19926 study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655381", 
            "org_study_id": "ML28174", 
            "secondary_id": "2011-005516-29"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "8 mg/kg iv every 4 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cahors", 
                        "country": "France", 
                        "zip": "46005"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mulhouse", 
                        "country": "France", 
                        "zip": "68070"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orleans", 
                        "country": "France", 
                        "zip": "45032"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open Label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de Securit\u00e9 du M\u00e9dicament ANSM"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy according to DAS28-ESR/SDAI/TJC/SJC", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Sustained drug-free remission according to DAS28-ESR/SDAI criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}